More Access To US Consumers Means More False Claims For COVID-19 Than Other Health Dangers
Executive Summary
While types of unsupported claims were no different than those advertisers made when US was hit it by other widespread health emergencies, digital capabilities made advertisers’ response to COVID-19 different, says Rich Cleland, FTC Consumer Protection Bureau attorney.
You may also be interested in...
FTC Expands Dietary Supplement Advertising Guidance To All Products Making Health-Related Claims
The Federal Trade Commission’s Health Products Compliance Guidance, published 20 December, expands the agency’s focus from dietary supplements to all products making health-related claims, providing the first update in 25 years on the FTC’s thinking on clear and conspicuous disclosures and competent and reliable scientific evidence.
False Treatment Claims Still A COVID-19 Symptom: FTC Files Complaint Against California Firm
FTC files complaint alleging Precision Patient Outcomes marketed a supplement as a treatment to mitigate the effects of COVID-19 after agency let the firm know it considered the claims false advertising.
Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use
CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.